Revolutionizing Rehabilitation: How Wearable Exoskeleton Devices Will Transform Patient Recovery in 2025 and Beyond. Explore Breakthroughs, Market Dynamics, and the Road Ahead.

• Executive Summary: 2025 Market Outlook and Key Takeaways
• Market Size, Growth Rate, and Forecasts (2025–2030)
• Technological Innovations: Robotics, AI, and Materials Advancements
• Leading Manufacturers and Industry Players (e.g., eksoBionics.com, rewalk.com, suitx.com)
• Clinical Applications: Neurological, Orthopedic, and Geriatric Rehabilitation
• Regulatory Landscape and Reimbursement Trends
• Adoption Barriers and Enablers: Cost, Training, and Patient Acceptance
• Regional Analysis: North America, Europe, Asia-Pacific, and Emerging Markets
• Strategic Partnerships, M&A, and Investment Trends
• Future Outlook: Next-Gen Exoskeletons and Long-Term Market Impact
• Sources & References

Executive Summary: 2025 Market Outlook and Key Takeaways

The wearable exoskeleton rehabilitation devices market is poised for significant growth in 2025, driven by technological advancements, expanding clinical applications, and increasing adoption in both healthcare and industrial settings. Exoskeletons—robotic wearable devices designed to support or enhance human movement—are increasingly being integrated into rehabilitation protocols for patients recovering from neurological injuries, musculoskeletal disorders, and age-related mobility impairments.

Key industry leaders such as Ekso Bionics, ReWalk Robotics, and CYBERDYNE Inc. continue to innovate, with new models offering improved ergonomics, lighter materials, and enhanced sensor integration. In 2025, these companies are expected to further expand their product portfolios, targeting both clinical rehabilitation centers and home-based therapy. For example, Ekso Bionics has been advancing its EksoNR platform, which is FDA-cleared for use with patients suffering from stroke, spinal cord injury, and acquired brain injury, and is now being adopted by leading rehabilitation hospitals worldwide.

Recent data from industry sources and company reports indicate a surge in demand for wearable exoskeletons, particularly in North America, Europe, and parts of Asia-Pacific. The growing prevalence of stroke and spinal cord injuries, coupled with an aging population, is fueling this demand. ReWalk Robotics has reported increased installations of its ReWalk Personal 6.0 system in both clinical and home environments, reflecting a broader trend toward patient-centered, at-home rehabilitation solutions.

Meanwhile, CYBERDYNE Inc. continues to expand the reach of its HAL (Hybrid Assistive Limb) exoskeleton, which is CE-marked and used in rehabilitation centers across Europe and Asia. The company is also exploring new applications in elderly care and industrial support, signaling a diversification of the exoskeleton market beyond traditional rehabilitation.

Looking ahead, the next few years are expected to see further integration of artificial intelligence and machine learning into exoskeleton systems, enabling more personalized and adaptive therapy. Partnerships between device manufacturers and healthcare providers are likely to accelerate, improving access and reimbursement pathways. As regulatory frameworks mature and clinical evidence accumulates, wearable exoskeletons are set to become a standard component of rehabilitation medicine, with the potential to transform outcomes for millions of patients worldwide.

Market Size, Growth Rate, and Forecasts (2025–2030)

The global market for wearable exoskeleton rehabilitation devices is poised for robust growth in 2025 and the subsequent years, driven by technological advancements, increasing prevalence of neurological and musculoskeletal disorders, and expanding applications in both clinical and home settings. As of 2025, leading manufacturers are reporting significant increases in demand, particularly for devices designed to assist with post-stroke rehabilitation, spinal cord injury recovery, and age-related mobility impairments.

Key industry players such as Ekso Bionics, ReWalk Robotics, and CYBERDYNE Inc. are expanding their product portfolios and global reach. Ekso Bionics has reported growing adoption of its EksoNR exoskeleton in rehabilitation centers across North America and Europe, while ReWalk Robotics continues to secure regulatory approvals and reimbursement pathways in new markets, further fueling market expansion. CYBERDYNE Inc. is also scaling up deployment of its HAL (Hybrid Assistive Limb) exoskeletons in Asia and Europe, targeting both clinical and home rehabilitation segments.

The market is expected to maintain a double-digit compound annual growth rate (CAGR) through 2030, with estimates from industry sources and company reports suggesting annual growth rates in the range of 15–20%. This acceleration is attributed to several factors: the aging global population, rising incidence of stroke and spinal cord injuries, and increasing investments in healthcare infrastructure. Additionally, the integration of artificial intelligence and advanced sensor technologies is enhancing device functionality, making exoskeletons more adaptive and user-friendly.

In 2025, the market is characterized by a shift toward lighter, more ergonomic, and cost-effective devices, enabling broader adoption beyond specialized rehabilitation centers. Companies such as SuitX (now part of Ottobock), Ottobock, and Bionik Laboratories are actively developing next-generation exoskeletons aimed at both clinical professionals and end-users for home-based therapy. These developments are expected to further expand the addressable market and drive sustained growth through 2030.

• North America and Europe remain the largest markets, but Asia-Pacific is projected to see the fastest growth due to increasing healthcare investments and supportive regulatory environments.
• Strategic partnerships between device manufacturers, rehabilitation clinics, and healthcare providers are accelerating market penetration and technology adoption.
• Reimbursement policies and clinical validation studies are expected to play a pivotal role in shaping market dynamics over the next five years.

Overall, the outlook for wearable exoskeleton rehabilitation devices from 2025 to 2030 is highly positive, with sustained innovation, expanding clinical evidence, and growing acceptance among healthcare professionals and patients alike.

Technological Innovations: Robotics, AI, and Materials Advancements

The landscape of wearable exoskeleton rehabilitation devices is undergoing rapid transformation in 2025, driven by advances in robotics, artificial intelligence (AI), and materials science. These innovations are enabling more effective, adaptive, and accessible solutions for patients with mobility impairments, particularly those recovering from stroke, spinal cord injuries, or neurological disorders.

Robotics technology has become increasingly sophisticated, with exoskeletons now offering multi-joint actuation, improved ergonomics, and real-time motion adaptation. Companies such as Ekso Bionics and ReWalk Robotics are at the forefront, providing FDA-cleared devices for both clinical and personal use. Their latest models incorporate modular designs and enhanced sensor arrays, allowing for more natural gait patterns and personalized therapy regimens. In 2025, Ekso Bionics has introduced updates to its EksoNR platform, focusing on improved user interface and expanded compatibility with tele-rehabilitation systems.

AI integration is a defining trend, enabling exoskeletons to deliver adaptive assistance based on real-time biomechanical feedback. Machine learning algorithms analyze user movement, fatigue levels, and rehabilitation progress, dynamically adjusting support levels. CYBERDYNE Inc. has advanced its HAL (Hybrid Assistive Limb) exoskeleton with AI-driven control systems that interpret bioelectrical signals, allowing for intuitive user-initiated movement. This technology is being deployed in rehabilitation centers across Asia and Europe, with ongoing clinical studies evaluating its long-term efficacy.

Materials science is also propelling the sector forward. The adoption of lightweight composites, such as carbon fiber and advanced polymers, has reduced device weight and improved wearer comfort. Ottobock, a global leader in orthotics and prosthetics, has leveraged these materials in its exoskeletons, focusing on both industrial and medical applications. Their latest models emphasize modularity and ease of donning, addressing a key barrier to widespread clinical adoption.

Looking ahead, the convergence of robotics, AI, and materials innovation is expected to yield exoskeletons that are more affordable, user-friendly, and effective. Industry collaborations with rehabilitation hospitals and research institutes are accelerating the translation of laboratory advances into real-world clinical practice. As regulatory pathways become clearer and reimbursement models evolve, the next few years are likely to see broader deployment of wearable exoskeletons, expanding access to high-quality rehabilitation for diverse patient populations.

Leading Manufacturers and Industry Players (e.g., eksoBionics.com, rewalk.com, suitx.com)

The wearable exoskeleton rehabilitation device sector in 2025 is characterized by rapid technological advancements and a growing roster of established and emerging manufacturers. These devices, designed to assist individuals with mobility impairments in regaining movement and independence, are increasingly being adopted in clinical, rehabilitation, and even home settings. The industry is led by a handful of pioneering companies, each contributing unique innovations and expanding the global reach of exoskeleton technology.

• Ekso Bionics Holdings, Inc. is widely recognized as a trailblazer in the exoskeleton field. The company’s flagship product, the EksoNR, is a robotic exoskeleton designed for neurorehabilitation, enabling patients with stroke, spinal cord injury, or other neurological conditions to stand and walk during therapy. Ekso Bionics has established partnerships with leading rehabilitation centers worldwide and continues to invest in research to enhance device adaptability and patient outcomes. The company’s focus on clinical validation and regulatory approvals has solidified its reputation as a trusted provider in the sector (Ekso Bionics Holdings, Inc.).
• ReWalk Robotics Ltd. is another prominent player, known for its FDA-cleared ReWalk Personal 6.0 system, which enables individuals with lower limb disabilities, particularly those with spinal cord injuries, to walk independently. ReWalk’s devices are used both in rehabilitation facilities and for personal use, reflecting the company’s commitment to improving quality of life and independence for users. In recent years, ReWalk has expanded its portfolio to include the ReStore soft exo-suit for stroke rehabilitation, further diversifying its offerings (ReWalk Robotics Ltd.).
• SUITX (a subsidiary of Ottobock SE & Co. KGaA) has gained attention for its modular exoskeletons, such as the Phoenix, which are designed for both rehabilitation and industrial applications. SUITX’s integration into Ottobock, a global leader in prosthetics and orthotics, has accelerated its R&D and market penetration, particularly in Europe and North America. The company’s focus on lightweight, user-friendly designs is helping to make exoskeletons more accessible to a broader patient population (SUITX; Ottobock SE & Co. KGaA).
• CYBERDYNE Inc., based in Japan, is renowned for its HAL (Hybrid Assistive Limb) exoskeleton, which is used in rehabilitation centers across Asia and Europe. CYBERDYNE’s technology leverages bioelectric signals to assist voluntary movement, and the company is actively expanding its clinical network and research collaborations to validate the efficacy of its devices in various neurological conditions (CYBERDYNE Inc.).
• Hocoma AG, part of the DIH Group, offers the Lokomat robotic gait training system, which, while not a wearable exoskeleton in the strictest sense, is a leading robotic rehabilitation device for walking therapy. Hocoma’s solutions are widely adopted in hospitals and rehabilitation centers globally, and the company continues to innovate in the field of robotic-assisted therapy (Hocoma AG).

Looking ahead, the exoskeleton rehabilitation device market is expected to see increased competition as new entrants emerge and established players expand their product lines. Key trends include the integration of artificial intelligence for personalized therapy, lighter and more ergonomic designs, and broader insurance coverage, which will likely drive adoption in both clinical and home environments. Strategic partnerships between device manufacturers, healthcare providers, and research institutions are anticipated to accelerate clinical validation and regulatory approvals, further propelling the sector’s growth through 2025 and beyond.

Clinical Applications: Neurological, Orthopedic, and Geriatric Rehabilitation

Wearable exoskeleton rehabilitation devices are increasingly transforming clinical practice across neurological, orthopedic, and geriatric rehabilitation domains. As of 2025, these robotic systems are being integrated into rehabilitation protocols in hospitals, outpatient clinics, and even home settings, driven by advances in sensor technology, artificial intelligence, and lightweight materials.

In neurological rehabilitation, exoskeletons are primarily used for patients recovering from stroke, spinal cord injury, or traumatic brain injury. Devices such as the Ekso Bionics EksoNR and ReWalk Robotics ReWalk Personal 6.0 are FDA-cleared for use in assisting gait training and improving mobility outcomes. Clinical studies and real-world deployments have shown that these devices can facilitate earlier and more intensive ambulation, which is associated with improved neuroplasticity and functional recovery. In 2024 and 2025, several rehabilitation centers in North America and Europe have expanded their exoskeleton fleets, citing improved patient engagement and measurable gains in walking speed and endurance.

Orthopedic rehabilitation is another area where wearable exoskeletons are gaining traction. Patients recovering from lower limb fractures, joint replacements, or musculoskeletal injuries benefit from devices that provide adjustable support and resistance, enabling safe, repetitive movement. Companies like CYBERDYNE Inc. offer the HAL (Hybrid Assistive Limb) exoskeleton, which is used in orthopedic clinics in Japan and Europe for post-surgical rehabilitation. The device leverages bioelectrical signals from the user’s muscles to provide tailored assistance, promoting muscle re-education and joint stability. In 2025, orthopedic clinics are increasingly adopting exoskeletons as adjuncts to conventional therapy, with early data suggesting reductions in recovery time and improved patient satisfaction.

Geriatric rehabilitation represents a rapidly expanding application, as aging populations drive demand for mobility solutions that address frailty, balance deficits, and fall risk. Lightweight, user-friendly exoskeletons such as the SUITX (now part of Ottobock) Phoenix and Wandercraft Atalante are being piloted in elder care facilities and outpatient programs. These devices are designed to support safe ambulation and reduce caregiver burden, with some models offering autonomous walking and balance assistance. In 2025, pilot programs in Europe and Asia are evaluating the impact of exoskeletons on fall prevention and quality of life in older adults, with preliminary results indicating increased independence and reduced hospitalization rates.

Looking ahead, the clinical outlook for wearable exoskeletons is optimistic. Ongoing improvements in device ergonomics, battery life, and adaptive control algorithms are expected to broaden their applicability and accessibility. As regulatory pathways become clearer and reimbursement models evolve, adoption in neurological, orthopedic, and geriatric rehabilitation is projected to accelerate, making exoskeletons a standard component of multidisciplinary care by the late 2020s.

Regulatory Landscape and Reimbursement Trends

The regulatory landscape for wearable exoskeleton rehabilitation devices is evolving rapidly in 2025, reflecting both technological advances and growing clinical adoption. In the United States, the Food and Drug Administration (FDA) continues to play a central role, classifying most lower-limb exoskeletons as Class II medical devices, which require 510(k) premarket notification. Notably, several leading manufacturers, such as Ekso Bionics and ReWalk Robotics, have secured FDA clearances for their rehabilitation exoskeletons, enabling their use in clinical and, increasingly, personal settings. The FDA’s ongoing engagement with industry stakeholders is expected to result in updated guidance documents by late 2025, clarifying requirements for safety, efficacy, and post-market surveillance.

In Europe, wearable exoskeletons are regulated under the Medical Device Regulation (MDR 2017/745), which imposes stricter clinical evidence and post-market monitoring obligations compared to the previous Medical Device Directive. Companies such as CYBERDYNE Inc. and Hocoma AG have adapted to these requirements, with their devices holding CE marks and being deployed in rehabilitation centers across the continent. The European regulatory environment is expected to further harmonize digital health and robotics standards, with new technical specifications anticipated from the European Committee for Standardization (CEN) by 2026.

Reimbursement remains a critical factor influencing adoption. In the U.S., the Centers for Medicare & Medicaid Services (CMS) has yet to establish a national coverage determination for exoskeletons, but several private insurers have begun to reimburse for device-assisted rehabilitation in select cases, particularly for spinal cord injury and stroke patients. ReWalk Robotics has reported successful reimbursement cases in both the U.S. and Germany, and is actively engaged in policy advocacy to expand coverage. In Germany, the statutory health insurance system (GKV) has recognized certain exoskeletons as assistive devices, allowing for partial or full reimbursement, a trend likely to influence other European markets.

Looking ahead, the regulatory and reimbursement outlook for wearable exoskeleton rehabilitation devices is cautiously optimistic. Ongoing clinical trials and real-world evidence generation are expected to support broader coverage decisions. Industry groups, such as the International Industry Society in Advanced Rehabilitation Technology (IISART), are collaborating with regulators to develop consensus standards and best practices. As device costs decrease and clinical benefits become more widely documented, regulatory pathways and reimbursement frameworks are anticipated to become more streamlined, supporting wider patient access by 2026 and beyond.

Adoption Barriers and Enablers: Cost, Training, and Patient Acceptance

The adoption of wearable exoskeleton rehabilitation devices in 2025 is shaped by a complex interplay of cost, training requirements, and patient acceptance. While technological advancements have made exoskeletons more accessible, several barriers persist, even as enablers continue to emerge.

Cost remains a primary barrier. Advanced exoskeletons for rehabilitation, such as those developed by ReWalk Robotics, Ekso Bionics, and CYBERDYNE Inc., often carry price tags ranging from $40,000 to over $100,000 per unit. These costs reflect sophisticated sensor arrays, actuators, and safety systems, as well as the need for ongoing maintenance and software updates. While some insurance providers in select markets have begun to reimburse for exoskeleton-assisted therapy, coverage remains inconsistent, limiting widespread adoption in clinics and home settings. Manufacturers are responding by exploring leasing models and modular designs to reduce upfront costs and improve affordability.

Training is another significant consideration. Effective use of exoskeletons requires specialized training for both clinicians and patients. Companies like Ekso Bionics and ReWalk Robotics have established certified training programs for rehabilitation professionals, focusing on device operation, patient safety, and therapy optimization. However, the learning curve can be steep, particularly for smaller clinics with limited resources. To address this, manufacturers are investing in intuitive user interfaces, remote support, and digital training modules, aiming to streamline onboarding and reduce the burden on healthcare staff.

Patient acceptance is influenced by device comfort, perceived benefit, and psychosocial factors. Early exoskeletons were often bulky and restrictive, but recent models from CYBERDYNE Inc. and Hocoma AG emphasize ergonomic design, lighter materials, and customizable fit. Clinical studies and real-world feedback indicate that patients are more likely to embrace exoskeleton therapy when they experience tangible improvements in mobility and independence. Nevertheless, some users express concerns about device stigma, fatigue, or the complexity of donning and doffing the equipment.

Looking ahead, the outlook for adoption is cautiously optimistic. Ongoing innovation, such as AI-driven gait adaptation and cloud-based performance monitoring, is expected to enhance usability and outcomes. As more clinical evidence accumulates and reimbursement pathways expand, wearable exoskeletons are poised to become a standard component of neurorehabilitation and mobility restoration in the coming years.

Regional Analysis: North America, Europe, Asia-Pacific, and Emerging Markets

The global landscape for wearable exoskeleton rehabilitation devices is rapidly evolving, with distinct regional dynamics shaping adoption and innovation. As of 2025, North America, Europe, Asia-Pacific, and emerging markets each present unique opportunities and challenges for the sector.

North America remains a frontrunner in both technological advancement and market adoption. The United States, in particular, benefits from robust investment in medical robotics and a strong network of rehabilitation centers. Companies such as Ekso Bionics and ReWalk Robotics are headquartered in the region and have established partnerships with leading hospitals and veterans’ organizations. The U.S. Food and Drug Administration (FDA) has cleared several exoskeleton devices for clinical and personal use, accelerating integration into rehabilitation protocols. Canada is also witnessing increased adoption, supported by public healthcare initiatives and collaborations with research institutions.

Europe is characterized by a strong regulatory framework and a focus on patient safety and efficacy. The region is home to innovative manufacturers such as Ottobock (Germany), which has expanded its exoskeleton portfolio for both rehabilitation and industrial applications. The European Union’s emphasis on medical device regulation (MDR) ensures high standards, but can also lengthen time-to-market. Nevertheless, countries like Germany, France, and the UK are investing in pilot programs within public health systems, and cross-border research initiatives are fostering further development.

Asia-Pacific is emerging as a dynamic growth engine, driven by demographic trends such as aging populations and rising incidence of stroke and spinal cord injuries. Japan and South Korea are at the forefront, with companies like CYBERDYNE Inc. commercializing exoskeletons for rehabilitation and elder care. China is rapidly scaling up domestic production and deployment, supported by government incentives and a burgeoning medtech sector. The region’s focus on cost-effective solutions and large-scale deployment is expected to drive significant market expansion through 2025 and beyond.

Emerging markets in Latin America, the Middle East, and parts of Africa are at an earlier stage of adoption. However, increasing awareness of rehabilitation technologies and international collaborations are beginning to open new opportunities. Local distributors are partnering with established manufacturers to introduce exoskeleton devices, and pilot projects are underway in select urban hospitals. While challenges such as cost and infrastructure persist, the outlook for gradual uptake is positive, especially as device prices decrease and training programs expand.

Across all regions, the next few years are expected to see continued growth, with advances in lightweight materials, AI-driven control systems, and tele-rehabilitation capabilities further enhancing the accessibility and effectiveness of wearable exoskeleton rehabilitation devices.

Strategic Partnerships, M&A, and Investment Trends

The wearable exoskeleton rehabilitation devices sector is experiencing a dynamic phase of strategic partnerships, mergers and acquisitions (M&A), and investment activity as of 2025. This momentum is driven by the convergence of robotics, medical technology, and digital health, with established players and innovative startups seeking to expand their technological capabilities, market reach, and clinical impact.

One of the most prominent companies in this space, Ekso Bionics, has continued to pursue strategic collaborations with rehabilitation centers and healthcare providers worldwide. In recent years, Ekso Bionics has entered into multiple partnership agreements to deploy its EksoNR exoskeleton in leading hospitals, aiming to accelerate patient access and gather real-world data to inform device improvements. The company’s approach includes working closely with physical therapy networks and integrating its devices into broader neurorehabilitation programs.

Another key player, ReWalk Robotics, has focused on expanding its global footprint through distribution partnerships and technology licensing. In 2024 and 2025, ReWalk has announced new alliances with medical device distributors in Europe and Asia, targeting both clinical and personal use markets. The company is also investing in R&D collaborations to enhance device ergonomics and software, reflecting a trend toward more user-friendly and adaptive exoskeletons.

The sector has also seen notable M&A activity. Ottobock, a global leader in prosthetics and orthotics, has been active in acquiring innovative startups specializing in wearable robotics. Ottobock’s acquisition strategy is aimed at integrating advanced exoskeleton technologies into its rehabilitation portfolio, leveraging its established distribution channels and clinical relationships. This consolidation is expected to accelerate the commercialization of next-generation exoskeletons and foster interoperability with other assistive devices.

Investment trends in 2025 indicate robust venture capital and corporate funding, particularly for companies developing AI-driven and lightweight exoskeletons. Startups are attracting funding rounds to support clinical trials, regulatory approvals, and market entry in North America, Europe, and Asia-Pacific. Strategic investors, including medical device manufacturers and rehabilitation service providers, are increasingly participating in these rounds to secure early access to breakthrough technologies.

Looking ahead, the outlook for strategic partnerships and investment in wearable exoskeleton rehabilitation devices remains strong. The sector is expected to witness further cross-industry collaborations, especially with digital health and sensor technology firms, to enable data-driven rehabilitation and remote patient monitoring. As reimbursement frameworks evolve and clinical evidence grows, M&A and partnership activity are likely to intensify, shaping a more integrated and patient-centric rehabilitation ecosystem.

Future Outlook: Next-Gen Exoskeletons and Long-Term Market Impact

The future outlook for wearable exoskeleton rehabilitation devices in 2025 and the coming years is marked by rapid technological advancements, expanding clinical adoption, and a growing focus on user-centric design. As the global population ages and the prevalence of neurological and musculoskeletal disorders rises, demand for effective rehabilitation solutions is intensifying. Exoskeletons—once largely experimental—are now entering mainstream rehabilitation settings, driven by improved safety, efficacy, and accessibility.

Key industry leaders are spearheading innovation. Ekso Bionics continues to refine its EksoNR exoskeleton, which is FDA-cleared for use with stroke and spinal cord injury patients. The company is investing in AI-driven gait analysis and adaptive assistance algorithms, aiming to personalize therapy and improve patient outcomes. Similarly, ReWalk Robotics is advancing its ReStore and ReWalk Personal systems, focusing on lightweight materials and enhanced mobility for both clinical and home use. In 2024, ReWalk received expanded regulatory clearances in Europe and North America, setting the stage for broader adoption in 2025.

Asian manufacturers are also making significant strides. CYBERDYNE Inc. of Japan, known for its HAL (Hybrid Assistive Limb) exoskeleton, is integrating cloud-based data analytics to support remote monitoring and tele-rehabilitation. This aligns with a broader industry trend toward digital health integration, enabling therapists to track progress and adjust protocols in real time.

The next generation of exoskeletons is expected to feature greater modularity, allowing customization for different patient needs and body types. Companies like Hocoma (a division of DIH Medical) are developing systems that combine robotic exoskeletons with virtual reality and gamified therapy, enhancing patient engagement and adherence. Meanwhile, SuitX (now part of Ottobock) is leveraging its expertise in industrial exoskeletons to inform the development of lighter, more ergonomic rehabilitation devices.

Looking ahead, the long-term market impact is expected to be substantial. As device costs decrease and reimbursement pathways improve, exoskeletons are poised to become a standard component of neurorehabilitation and post-acute care. Ongoing clinical trials and real-world evidence will further validate their benefits, potentially expanding indications to include pediatric and geriatric populations. The convergence of robotics, AI, and digital health is set to transform rehabilitation, offering new hope for millions of patients worldwide.

Sources & References

• ReWalk Robotics
• CYBERDYNE Inc.
• ReWalk Robotics
• CYBERDYNE Inc.
• SuitX
• Ottobock
• Ekso Bionics
• Ottobock
• Ekso Bionics Holdings, Inc.
• Hocoma AG
• Hocoma AG
• SuitX